Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Incidence, risk factors, and consequences of human alphaherpesvirus infections in patients with psoriasis who initiate methotrexate or biologic agents

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Exploration of the induced cytokine responses in European Lyme neuroborreliosis: A longitudinal cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Non-alcoholic fatty liver disease is not a causal risk factor for psoriasis: A Mendelian randomization study of 108,835 individuals

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Can patient-reported outcome measures be used to predict consultation needs in patients with psoriasis? A survey study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Comorbidities in Chilean patients with psoriasis: a Global Healthcare Study on Psoriasis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Immunosuppressive agents may increase the risk of infections with human alphaherpesviruses.

METHODS: We included all adult patients with moderate to severe psoriasis who initiated methotrexate (MTX) or biologic agents in a retrospective cohort study. An episode of alphaherpesviruses infection was defined as filling a prescription for systemic acyclovir, valacyclovir, or famciclovir. Using nationwide registries, we determined the incidence, risk factors, 180-day hospital contacts, and 30-day mortality following infection.

RESULTS: We included 7294 patients; 4978 (68%) received MTX, and 2316 (32%) biologic agents. The incidence rates (95% confidence intervals) of alphaherpesviruses were 23 (20-27), 26 (19-35), 17 (11-27), and 6.7 (1.3-21) per 1000 person-years of follow-up in patients on MTX, tumor necrosis factor alpha (TNF-α) inhibitors, interleukin 12/23 (IL-12/23) inhibitors, and interleukin 17 (IL-17) inhibitors, respectively. Males had an unadjusted hazard ratio (HR) of 0.47 (P < .001) for alphaherpesvirus infection. Patients on IL-17 inhibitors had an adjusted HR of 0.24 (P = .048) compared to TNF-α inhibitors. Within 180 days after infection, 13%, 7.5%, and <0.5% of patients on MTX, TNF-α inhibitors, and IL-12/23 or IL-17 inhibitors, respectively, had hospital contacts, and the 30-day mortality for all groups was <0.5%.

CONCLUSIONS: The incidence and risk of alphaherpesvirus infections were comparable between patients on MTX and TNF-α inhibitors, whereas use of IL-17 inhibitors was associated with a lower risk.

Original languageEnglish
JournalThe Journal of infectious diseases
Volume226
Issue number9
Pages (from-to)1510-1518
ISSN0022-1899
DOIs
Publication statusPublished - 2022

Bibliographical note

© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

ID: 84497203